WO2025209574A1 - Inhibiteur de parp7 pour la prévention ou le traitement de tumeurs - Google Patents

Inhibiteur de parp7 pour la prévention ou le traitement de tumeurs

Info

Publication number
WO2025209574A1
WO2025209574A1 PCT/CN2025/087155 CN2025087155W WO2025209574A1 WO 2025209574 A1 WO2025209574 A1 WO 2025209574A1 CN 2025087155 W CN2025087155 W CN 2025087155W WO 2025209574 A1 WO2025209574 A1 WO 2025209574A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
independently
cancer
use according
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/CN2025/087155
Other languages
English (en)
Chinese (zh)
Inventor
叶飞
魏用刚
刘锐
朱钰沁
孙毅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kangbaida (Sichuan) Biotechnology Co Ltd
Original Assignee
Kangbaida (Sichuan) Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kangbaida (Sichuan) Biotechnology Co Ltd filed Critical Kangbaida (Sichuan) Biotechnology Co Ltd
Publication of WO2025209574A1 publication Critical patent/WO2025209574A1/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • Cancer is a major disease that affects human health and has become one of the most common diseases.
  • the heterogeneity and dynamic characteristics of tumors pose severe challenges to tumor treatment; at the same time, the interaction and dynamic changes between tumors and the microenvironment make tumor treatment more complex and difficult.
  • chemotherapy is one of the commonly used methods, but due to its low specificity, large adverse reactions, easy to develop drug resistance with long-term use, high mortality, recurrence and metastasis, etc., cancer patients bear a heavy disease burden and there are huge unmet needs. Therefore, new treatment methods are urgently needed.
  • TCDD 2,3,7,8-Tetrachlorodibenzo-p-dioxin
  • PARP7 2,3,7,8-Tetrachlorodibenzo-p-dioxin-inducible poly (ADP-ribose) polymerase
  • TCDD activates the aryl hydrocarbon receptor (AHR) and upregulates its expression.
  • One or more embodiments of the present application provide PARP7 inhibitors as active ingredients for treating and/or preventing cancer or tumors, so as to overcome the deficiencies of the prior art.
  • One or more embodiments of the present application provide use of a PARP7 inhibitor in the preparation of a medicament for treating and/or preventing cancer or tumors.
  • One or more embodiments of the present application provide the PARP7 inhibitor of the present application, which is used for treating and/or preventing cancer or tumors.
  • the PARP7 inhibitor of the present application is or a pharmaceutically acceptable salt thereof.
  • the PARP7 inhibitor is selected from RBN-2397, ONO-7119, QLS1103, JAB-26766, NSP-5020, NSP-5033, EB400, or a compound represented by formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof:
  • X 3 and X 4 are each independently C or N;
  • R 1a and R 1b are each independently H, D or C 1-6 alkyl; or R 1a , R 1b and the carbon atom to which they are connected form a 3- to 5-membered cycloalkyl;
  • R 2a and R 2b are each independently H, D or C 1-6 alkyl; or R 2a , R 2b and the carbon atom to which they are connected form a 3- to 5-membered cycloalkyl;
  • R 3 is H, D, C 1-6 alkyl, halogen or cyano, wherein the C 1-6 alkyl is optionally substituted with 1 to 3 halogens;
  • R 4 and R 5 are each independently H, D or C 1-6 alkyl; or R 4 , R 5 and the carbon atom to which they are connected form a 3- to 5-membered cycloalkyl group;
  • R 8 and R 9 are each independently H, D or C 1-6 alkyl; or R 8 , R 9 and the carbon atom to which they are connected form C ⁇ O; or R 8 and R 9 and the carbon atom to which they are connected form a 3- to 5-membered cycloalkyl;
  • R 10 is each independently C 1-6 alkyl, C 1-6 alkoxy, CONR 10a R 10b , halogen, cyano, S(O) 2 R 10c , SR 10d or 3- to 5-membered cycloalkyl, wherein the C 1-6 alkyl or C 1-6 alkoxy is optionally substituted with 1 to 3 halogens;
  • n 1, 2, or 3;
  • X 1 is NH, O or a 4- to 6-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N and O;
  • X 3 and X 4 are each independently C or N;
  • R 1a and R 1b are each independently H, D or C 1-6 alkyl
  • R 4 and R 5 are each independently H, D or C 1-6 alkyl; or R 4 , R 5 and the carbon atom to which they are connected form a 3- to 5-membered cycloalkyl group;
  • R 6 and R 7 are each independently H, D or C 1-6 alkyl
  • R 10 is each independently C 1-6 alkyl, C 1-6 alkoxy, CONR 10a R 10b , halogen, cyano, S(O) 2 R 10c , SR 10d or 3- to 5-membered cycloalkyl, wherein the C 1-6 alkyl or C 1-6 alkoxy is optionally substituted with 1 to 3 halogens;
  • R a is C 1-6 alkyl, C 3-5 cycloalkyl, halogen or cyano, wherein the C 1-6 alkyl is optionally substituted by 1 to 3 halogens;
  • B is a 5- to 6-membered carbocyclic or heterocyclic ring containing 1 to 3 heteroatoms selected from N, O and S;
  • n 1, 2, or 3;
  • n 0, 1, 2, or 3;
  • p 0, 1, 2 or 3.
  • the compound represented by formula (I) has the structure of formula (I-1):
  • X 1 is NH or a 4- to 6-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N and O;
  • X 2 is 0;
  • X 3 and X 4 are each independently C or N;
  • R 6 and R 7 are each independently H, D or C 1-6 alkyl
  • R 10d is H, D or C 1-6 alkyl
  • n 1, 2, or 3;
  • R 4 and R 5 are each independently H, D or C 1-6 alkyl
  • R 6 and R 7 are each independently H, D or C 1-6 alkyl
  • R 10 is C 1-6 alkyl, cyano, or SR 10d , wherein the C 1-6 alkyl is optionally substituted with 1 to 3 halogens;
  • R 10d is H, D or C 1-6 alkyl
  • R 1a and R 1b are each independently selected from H, D or C 1-6 alkyl
  • R 2a and R 2b are each independently selected from H, D or C 1-6 alkyl
  • R 3 is H, D, C 1-6 alkyl or halogen, wherein the C 1-6 alkyl is optionally substituted with 1 to 3 halogens;
  • R 4 and R 5 are each independently H or D;
  • R 8 and R 9 are each independently H or D;
  • R 10 is CF 3 or SR 10d ;
  • R 10d is H, D or C 1-6 alkyl
  • n 1, 2, or 3;
  • n 0, 1, 2 or 3.
  • X is selected from NH
  • X 2 is selected from O;
  • R 1a and R 1b are each independently selected from H, D or C 1-3 alkyl
  • R 2a and R 2b are each independently selected from H, D or C 1-3 alkyl
  • R 10 is CF 3 ;
  • n 0, 1 or 2.
  • R 4 and R 5 are each independently H, D or C 1-6 alkyl
  • R 6 and R 7 are each independently H, D or C 1-6 alkyl
  • R 10 is C 1-6 alkyl, C 1-6 alkoxy, cyano or SR 10d , wherein the C 1-6 alkyl or C 1-6 alkoxy is optionally substituted with 1 to 3 halogens;
  • R 10d is H, D or C 1-6 alkyl
  • n 1, 2, or 3;
  • R 4 and R 5 are each independently H, D or C 1-3 alkyl
  • R 10 is C 1-6 alkyl, cyano or SR 10d , wherein the C 1-6 alkyl is optionally substituted with 1 to 3 halogens;
  • R 10d is H, D or C 1-6 alkyl
  • n 1, 2, or 3;
  • n 0, 1 or 2.
  • X 1 is NH
  • X 2 is 0;
  • R 1a and R 1b are each independently H, D or C 1-3 alkyl
  • R 2a and R 2b are each independently H or D;
  • R 4 and R 5 are each independently H or D;
  • R 6 and R 7 are each independently H or D;
  • R 10 is CF 3 ;
  • n 1, 2, or 3:
  • the PARP7 inhibitor is the following compound:
  • the PARP7 inhibitor is contained in a pharmaceutical composition that further comprises one or more pharmaceutically acceptable excipients, diluents, or carriers.
  • the tumor is selected from solid tumors and/or hematological tumors.
  • the tumor is selected from malignant solid tumors.
  • the tumor is selected from advanced malignant solid tumors.
  • the solid tumor is selected from colorectal cancer, breast cancer, central nervous system cancer, uterine cancer, cervical cancer, kidney cancer, adrenal cancer, lung cancer, esophageal cancer, head and neck cancer, ovarian cancer, pancreatic cancer, liver cancer, prostate cancer, endometrial cancer, testicular cancer, gastric cancer, laryngeal cancer, urinary tract cancer, bladder cancer, colon cancer, rectal cancer, thyroid cancer, bone cancer, epithelial cancer, bile duct cancer, gallbladder cancer, skin cancer, mesothelioma, basal cell carcinoma, adenoid cystic carcinoma, leiomyosarcoma, gastrointestinal stromal tumor, Ewing sarcoma, Kaposi sarcoma, or a PARP7-amplified advanced solid tumor.
  • the hematological tumor is selected from the group consisting of leukemia, myeloma, and lymphoma.
  • the hematological neoplasm is selected from Hodgkin's lymphoma or non-Hodgkin's lymphoma, multiple myeloma, B-cell lymphoma, small lymphocytic lymphoma, T-cell lymphoma, hairy cell lymphoma, Burkett's lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia.
  • the lung cancer is non-small cell lung cancer or neuroendocrine lung cancer.
  • the non-small cell lung cancer is lung squamous cell carcinoma or lung adenocarcinoma.
  • the head and neck cancer is selected from head and neck squamous cell carcinoma.
  • the liver cancer is hepatocellular carcinoma.
  • the daily dose of the PARP7 inhibitor is 50 to 2000 mg/day.
  • the daily dose of the PARP7 inhibitor is 100-1500 mg/day.
  • the PARP7 inhibitor is administered three times a day, twice a day, once a day, once every two days, once every three days, once every four days, once every five days, once every six days, once a week, once every two weeks, once every three weeks, or once every four weeks.
  • the daily dose of the PARP7 inhibitor is 25 to 100 mg BID.
  • the daily dose of the PARP7 inhibitor is 50 to 750 mg BID.
  • the daily dose of the PARP7 inhibitor is 100-500 mg BID.
  • the total daily dose of the PARP7 inhibitor is selected from 50-1500 mg, such as 100-1000 mg, measured as the free base.
  • Heterocycloalkyl refers to a substituted or unsubstituted saturated non-aromatic ring group, which can be a 3-8 membered (e.g., 3, 4, 5, 6, 7, 8 membered) monocyclic ring, a 4-12 membered (e.g., 4, 5, 6, 7, 8, 9, 10, 11, 12 membered) bicyclic ring, or a 10-15 membered (e.g., 10, 11, 12, 13, 14, 15 membered) tricyclic ring system, and contains 1, 2, or 3 heteroatoms selected from N, O, or S, preferably a 3- to 8-membered heterocyclic ring.
  • the 1, 2, or 3 N or S atoms optionally substituted in the "heterocycloalkyl” ring can be oxidized to various oxidation states; the "heterocycloalkyl” can be attached to a heteroatom or a carbon atom; the “heterocycloalkyl” can be a bridged ring or a spirocyclic ring.
  • Tautomers or “tautomeric forms” refer to structural isomers of different energies that are interconvertible via a low energy barrier.
  • proton tautomers also known as prototropic tautomers
  • proton migration such as keto-enol isomerization, imine-enamine isomerization, lactam-lactim isomerization, and the like.
  • present disclosure includes tautomers of any of the described compounds.
  • “Pharmaceutically acceptable salt” or “pharmaceutically acceptable salt thereof” refers to a salt of the compound of the present invention that retains the biological effectiveness and properties of the free acid or free base, and the free acid is obtained by reacting with a non-toxic inorganic base or organic base, or the free base is obtained by reacting with a non-toxic inorganic acid or organic acid.
  • Optional or “optionally” or “selectively” or “optionally” means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
  • a heterocyclyl optionally substituted with an alkyl group means that the alkyl group may but need not be present, and that the description includes instances where the heterocyclyl group is substituted with an alkyl group and instances where the heterocyclyl group is not substituted with an alkyl group.
  • FIG2 shows the body weight change curve of tumor-bearing mice in Example 1.
  • FIG3 is a curve showing the change in tumor volume of the NCI-H1373 mouse tumor-bearing model in Example 2.
  • FIG4 is a curve showing the weight change rate of mice in the NCI-H1373 mouse tumor-bearing model in Example 2.
  • FIG5 is a curve showing the change in tumor volume of MDA-MB-231 subcutaneous humanized model mice in Example 3.
  • FIG6 is a curve showing the change in tumor volume of HCC827 subcutaneous humanized model mice in Example 4.
  • the compound of formula (I) or its specific structure according to the present invention can be prepared by the method of patent WO2022242750A1.
  • compound A used in the embodiment of the present invention is compound 1 in patent WO2022242750A1.
  • test substance was prepared using DMSO + 30% HP- ⁇ -CD at a ratio of 5/95 (v/v) and administered by gavage at a dosage of 5 mL/kg for a total of 17 days.
  • tumor volume and animal body weight were measured twice a week and the tumor growth and body weight change curves were plotted, as shown in Figures 1 and 2.
  • Human lung cancer cell line NCI-H1373 (Nanjing Kebai Biotechnology Co., Ltd., catalog number CBP60162) was cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum. When the cells reached the exponential growth phase, they were trypsinized, collected, counted, and resuspended in PBS before being inoculated subcutaneously into the right flank of female CB17 SCID mice.
  • the inoculation volume was 200 ⁇ L (100 ⁇ L NCI-H1373 cells + 100 ⁇ L Matrigel mixture) at a density of 5 ⁇ 10 6 cells per mouse.
  • mice When the average tumor volume reached approximately 120 mm 3 , 24 mice were enrolled and randomly assigned to three experimental groups of 8 mice each: a blank group, a compound A (100 mg/kg, BID) group, and a RBN-2397 (100 mg/kg, BID) group. Compound A and RBN-2397 were prepared using 0.5% MC and administered orally at a volume of 10 mL/kg. During dosing, tumor volume was measured twice weekly, and tumor growth curves were plotted. Mice were weighed twice weekly to calculate the rate of weight change, as shown in Figures 3 and 4.
  • MDA-MB-231 cells human breast cancer cells
  • Leibovitz's L-15 medium containing 10% fetal bovine serum, 1% penicillin-streptomycin solution, and 0.01 mg/mL insulin.
  • the cells reached the exponential growth phase, they were trypsinized, collected, counted, resuspended in DPBS, and inoculated subcutaneously on the right back of female C-NKG mice at a cell density of 1 ⁇ 107 cells/mouse in a volume of 200 ⁇ L.
  • mice Frozen PBMCs were resuscitated, resuspended in DPBS, and inoculated into the tail vein of the mice at a cell density of 5 ⁇ 106 cells/mouse in a volume of 200 ⁇ L.
  • a blank group 12 mice were selected based on tumor volume and mouse body weight and randomly assigned to two experimental groups of 6 mice each: a blank group and a compound A (125 mg/kg, BID) treatment group.
  • Compound A was prepared using DMSO + 30% HP- ⁇ -CD (5:95, v/v) and administered orally at a volume of 10 mL/kg.
  • tumor volume was measured twice weekly, and tumor growth curves were plotted. Mice were weighed twice weekly to calculate the rate of weight change. At the end of the experiment, tumors were removed, weighed, and photographed. The tumor growth curve is shown in Figure 5.
  • Compound A has a good tumor inhibitory effect on human breast cancer cells in the MDA-MB-231 model.
  • HCC827 cells human non-small cell lung cancer cells
  • RPMI-1640 medium containing 10% fetal bovine serum, 1% penicillin-streptomycin solution, and 0.01 mg/mL insulin.
  • the cells were in the exponential growth phase, they were trypsinized, collected, counted, resuspended in DPBS, and inoculated subcutaneously on the right back of female B-NDG mice.
  • the inoculation volume was 200 ⁇ L.
  • Frozen PBMCs were resuscitated, resuspended in DPBS , and inoculated into the tail vein of the mice.
  • the inoculation volume was 1 ⁇ 10 7 cells per mouse.
  • the inoculation volume was 200 ⁇ L.
  • mice When the average tumor volume reached approximately 80-120 mm3, 12 mice were selected based on tumor volume and mouse body weight and randomly assigned to two experimental groups, with 6 mice in each group. The groups were set as a blank group and a compound A (125 mg/kg, BID) treatment group.
  • Compound A was prepared with DMSO + 30% HP- ⁇ -CD (5:95, v/v) and administered orally at a volume of 10 mL/kg. During the administration period, tumor volume was measured twice a week and a tumor growth curve was plotted, as shown in FIG6 .
  • Compound A has a good tumor inhibitory effect on human non-small cell lung cancer cells in the HCC827 model.
  • MC38.hVEGFA cells (mouse colon carcinoma cells) were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin solution, and 0.01 mg/mL insulin. When the cells reached the exponential growth phase, they were trypsinized, harvested, counted, resuspended in DPBS, and inoculated subcutaneously on the right dorsal surface of female B-hPD-1/hPD- L1 /hVEGFA mice at a seeding volume of 100 ⁇ L.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Inhibiteur de PARP7 pour le traitement et/ou la prévention de tumeurs.
PCT/CN2025/087155 2024-04-03 2025-04-03 Inhibiteur de parp7 pour la prévention ou le traitement de tumeurs Pending WO2025209574A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN202410399102 2024-04-03
CN202410399102.9 2024-04-03
CN202411086020.5 2024-08-08
CN202411086020 2024-08-08
CN202411703469 2024-11-26
CN202411703469.1 2024-11-26

Publications (1)

Publication Number Publication Date
WO2025209574A1 true WO2025209574A1 (fr) 2025-10-09

Family

ID=97266491

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2025/087155 Pending WO2025209574A1 (fr) 2024-04-03 2025-04-03 Inhibiteur de parp7 pour la prévention ou le traitement de tumeurs

Country Status (1)

Country Link
WO (1) WO2025209574A1 (fr)

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180318295A1 (en) * 2015-11-04 2018-11-08 Astellas Pharma Inc. Pharmaceutical composition for cancer immunotherapy and/or immunological activation containing diamino heterocyclic carboxamide compound as active ingredient
CN112424188A (zh) * 2018-04-30 2021-02-26 里邦医疗公司 作为parp7抑制剂的哒嗪酮
CN112939947A (zh) * 2021-03-05 2021-06-11 中国医科大学 Parp7小分子抑制剂的化合物及其应用
WO2022242750A1 (fr) * 2021-05-21 2022-11-24 成都百裕制药股份有限公司 Dérivé de pipérazine et son utilisation en médecine
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药（上海）有限公司 作为parp7抑制剂的哒嗪酮类化合物
CN116396228A (zh) * 2023-03-31 2023-07-07 上海湃隆生物科技有限公司 尿嘧啶类parp7抑制剂
WO2024032409A1 (fr) * 2022-08-09 2024-02-15 成都百裕制药股份有限公司 Utilisation d'un composé pipérazine en association avec une radiothérapie pour le traitement d'une tumeur
WO2024032410A1 (fr) * 2022-08-09 2024-02-15 成都百裕制药股份有限公司 Composition à base d'un composé pipérazine et d'un inhibiteur de pd-1 ou d'un inhibiteur de pd-l1 et son utilisation dans le traitement de tumeurs
WO2024061554A1 (fr) * 2022-09-22 2024-03-28 Duke Street Bio Limited Composé pharmaceutique
CN118027039A (zh) * 2022-11-14 2024-05-14 成都百裕制药股份有限公司 一种取代的哌嗪衍生物的晶体及其制备方法
WO2025036478A1 (fr) * 2023-08-17 2025-02-20 康百达（四川）生物医药科技有限公司 Préparation pharmaceutique de dérivé de pipérazine, son procédé de préparation et son utilisation
WO2025103341A1 (fr) * 2023-11-13 2025-05-22 康百达（四川）生物医药科技有限公司 Combinaison pharmaceutique d'un médicament combiné à un inhibiteur de parp7, et son utilisation dans le traitement de tumeurs

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180318295A1 (en) * 2015-11-04 2018-11-08 Astellas Pharma Inc. Pharmaceutical composition for cancer immunotherapy and/or immunological activation containing diamino heterocyclic carboxamide compound as active ingredient
CN112424188A (zh) * 2018-04-30 2021-02-26 里邦医疗公司 作为parp7抑制剂的哒嗪酮
CN112939947A (zh) * 2021-03-05 2021-06-11 中国医科大学 Parp7小分子抑制剂的化合物及其应用
WO2022242750A1 (fr) * 2021-05-21 2022-11-24 成都百裕制药股份有限公司 Dérivé de pipérazine et son utilisation en médecine
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药（上海）有限公司 作为parp7抑制剂的哒嗪酮类化合物
WO2024032409A1 (fr) * 2022-08-09 2024-02-15 成都百裕制药股份有限公司 Utilisation d'un composé pipérazine en association avec une radiothérapie pour le traitement d'une tumeur
WO2024032410A1 (fr) * 2022-08-09 2024-02-15 成都百裕制药股份有限公司 Composition à base d'un composé pipérazine et d'un inhibiteur de pd-1 ou d'un inhibiteur de pd-l1 et son utilisation dans le traitement de tumeurs
WO2024061554A1 (fr) * 2022-09-22 2024-03-28 Duke Street Bio Limited Composé pharmaceutique
CN118027039A (zh) * 2022-11-14 2024-05-14 成都百裕制药股份有限公司 一种取代的哌嗪衍生物的晶体及其制备方法
CN116396228A (zh) * 2023-03-31 2023-07-07 上海湃隆生物科技有限公司 尿嘧啶类parp7抑制剂
WO2025036478A1 (fr) * 2023-08-17 2025-02-20 康百达（四川）生物医药科技有限公司 Préparation pharmaceutique de dérivé de pipérazine, son procédé de préparation et son utilisation
WO2025103341A1 (fr) * 2023-11-13 2025-05-22 康百达（四川）生物医药科技有限公司 Combinaison pharmaceutique d'un médicament combiné à un inhibiteur de parp7, et son utilisation dans le traitement de tumeurs

Similar Documents

Publication Publication Date Title
CN111225911B (zh) 用于治疗血液病的化合物和组合物
KR102633530B1 (ko) 혈액 장애를 치료하기 위한 화합물 및 조성물
EP3277276B1 (fr) Procédés d'administration d'inhibiteurs de glutaminase
US12156861B2 (en) Pharmaceutical composition for treating kidney cancer and application thereof
EP3229796B1 (fr) Combinaison d'un derive 6-oxo-1,6-dihydro-pyridazine ayant une activite anti-tumeureuse avec un derive de quinazoline
CN113811302B (zh) 激酶抑制剂的用途
CN114732807A (zh) 米托蒽醌在制备预防或治疗急性移植物抗宿主病药物中的应用
CN113527301B (zh) 含四嗪取代基的芳并异硒唑类化合物及其合成方法和应用
AU2004220205A1 (en) Antitumor effect potentiator and antitumor agent
US9862741B2 (en) Cytidine derivative dimers and applications thereof
CN102942530A (zh) 一种新型抗肿瘤化合物及其药物组合物
EP2906294B1 (fr) Association d'un dérivé de 6-oxo-1,6-dihydro-pyridazine présentant une activité anticancéreuse à un inhibiteur de mek
CA2935892C (fr) Association d'un derive de 6-oxo-1,6-dihydro-pyridazine ayant une activite anticancereuse avec du gefitinib
EP1530494B1 (fr) Preparation pharmaceutique contenant des composes a base de complexes de palladium
CN112535686B (zh) 激酶抑制剂的新用途
HK40031549A (en) Compounds and compositions for treating hematological disorders
EP3116882A2 (fr) Composés visant à supprimer ou inhiber la prolifération des cellules souches cancéreuses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25781775

Country of ref document: EP

Kind code of ref document: A1